Scholars Central

Conference abstractPublished 23 Nov 2012

Global biotechnology product registration U.S and European Union

Authors: Samudrala Prathima, Sruthi Konangi, N.Vishal Gupta, H.V.Raghunandan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biotechnology research continually opens opportunities for the development of new biopharmaceuticals for human use. Consequently, integration of public healthcare and human welfare with the business of biotechnology is becoming a central challenge. However, the companies developing such products are often small and they may have insufficient knowledge of the possible regulatory aspects concerning such new products. Like major pharmaceutical firms, today's biotechnology companies must leverage their development programs internationally and penetrate global markets to remain competitive. To maximize market penetration, most biologics developers are targeting the largest international markets for new medicines -the U.S. & European Union. Within these two "prize" markets, fundamental regulatory changes affecting biotechnology product regulation have been implemented recently. The United States and the European Union share a common desire to provide a safe food supply and credible regulatory systems. However, they have adopted two very different regulatory approaches to deal with the increasing numbers of GM (genetically modified) food and feed products coming to market. European Medicines Evaluation Agency (EMEA) was installed as the regulatory gatekeeper for the European market. EU established that the EMEA's new centralized procedure would be mandatory for virtually all significant biopharmaceutical products. The U.S. module of Global Biotechnology Product Registration is the first to provide a comprehensive and up-to-date analysis of the post-reform FDA Center for Biologics Evaluation and Research and its new licensing process for therapeutic recombinant DNA-derived products and in vivo monoclonal antibody products. This module covers the complete U.S. biotech product approval process, from preclinical testing to post marketing regulatory requirements.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Pharmaceutical Regulatory Affairs: Open Access.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalPharmaceutical Regulatory Affairs: Open Access
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Samudrala Prathima”
  • BylineArticles whose byline prints “Sruthi Konangi”
  • BylineArticles whose byline prints “N.Vishal Gupta”
  • BylineArticles whose byline prints “H.V.Raghunandan”